Inhibition of dipeptidyl peptidase IV (DPP-IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.
What does DPPIV stand for?
DPPIV stands for Dipeptidyl Peptidase IV
This definition appears frequently
- Doctoral Programs in Public Health (University of Tampere; Tampere, Finland)
- Don't Post Porn Here
- Duodenum-Preserving Pancreatic Head Resection (surgery)
- Designing Pleasurable Products and Interfaces (international conference)
- Diastole-Phased Pulsatile Infusion
- Diesel Performance Parts, Inc. (Nashville, TN)
- Dipeptidyl Peptidase I
- Disability Pregnancy and Parenthood International (UK)
- Disaster Preparedness and Prevention Initiative
- Dossier Patient Partagé Informatisé (French: Shared Computerized Patient Record)
- Des Petits Papiers Jaunes (French: Little Yellow Paper)
- Dana Pensiun Pemberi Kerja (Indonesian: Employers Pension Fund)
- Dewan Pemuda PAS Kawasan Dungun
- Deer Park Public Library (Texas and New York)
- Des Plaines Public Library (Des Plaines, Illinois)
- Digital Peer Publishing Licence (Germany)
- Découverte Pêche et Protection des Milieux (French: Fishing Discovery and Environmental Protection)
- Defective Parts Per Million (Six Sigma metric, manufacturing)
- Defence Policy Procurement Manual (Australia)
- Differential Pulse Position Modulation
Samples in periodicals archive:
Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
The key enzyme in Gluten Defense, a formula designed to help digest hidden gluten and casein, is dipeptidyl peptidase IV.
The Pharmacor advisory service entitled Type 2 Diabetes finds that the dipeptidyl peptidase IV (DPP-IV) inhibitor drug class will continue to experience robust growth, given their increasing use in the second-line setting, and will hold a 28 percent market share by 2021.
is a dipeptidyl peptidase IV (DPP-4) inhibitor for the treatment of type 2 diabetes.
Tokyo, Japan, July 14, 2005 - (JCNN) - Takeda Pharmaceutical (TSE: 4502) announced on July 14 that it has agreed with Pharmaceutical Product Development (PPD), a US pharmaceutical company, concerning rights to the dipeptidyl peptidase IV (DPP4) inhibitor
is a dipeptidyl peptidase IV (DPP-4) inhibitor being reviewed as an adjunct to diet and exercise for the treatment of type 2 diabetes.
PPD is partnering with Takeda to develop alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.